Other promising clinical results demonstrated that Pexa-Vec treatment elevated IFN-γ and tumor necrosis factor (TNF)-α in tumor sites to lead to activation and/or recruitment of neutrophils, eosinophils, and lymphocytes to the tumor tissues, ultimately suggesting immune activation at injected tissues (79–82). This evidence concerns the gene TNF and neoplasm.